For the quarter ending 2025-09-30.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Total revenue | - | - | - | 8,018,692.5 |
| Research and development | 20,359,098 | 22,047,254 | 18,915,572 | 12,827,974.5 |
| General and administrative | 5,924,942 | 5,671,880 | 6,067,376 | 4,172,589.5 |
| Total operating expenses | 26,284,040 | 27,719,134 | 24,982,948 | 17,000,564 |
| Loss from operations | -26,284,040 | -27,719,134 | -24,982,948 | -8,981,871.5 |
| Other income | 6,740 | 14,991 | 12,485 | 1,867.75 |
| Investment income | 1,713,499 | 1,793,352 | 729,542 | 552,867 |
| Loss on disposal of fixed assets | -6,846 | - | -150,673 | -28,201.25 |
| Total other income (expense) | 1,713,393 | 1,808,343 | 591,354 | 526,533.5 |
| Net loss | -24,570,647 | -25,910,791 | -24,391,594 | -8,455,338 |
| Net unrealized loss on marketable securities | -543,452 | -424,353 | 784,972 | 501,311 |
| Comprehensive loss | -25,114,099 | -26,335,144 | -23,606,622 | -7,954,027 |
| Earnings per share, basic | -0.54 | -0.57 | -0.53 | -0.21 |
| Earnings per share, diluted | -0.54 | -0.57 | -0.53 | -0.21 |
| Weighted average number of shares outstanding, basic | 45,716,151 | 45,709,071 | 45,636,633 | -14,856,699.5 |
| Weighted average number of shares outstanding, diluted | 45,716,151 | 45,709,071 | 45,636,633 | -14,856,699.5 |
CAPRICOR THERAPEUTICS, INC. (CAPR)
CAPRICOR THERAPEUTICS, INC. (CAPR)